Toth Financial Advisory Corp bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the first quarter, HoldingsChannel reports. The institutional investor bought 21,325 shares of the biotechnology company’s stock, valued at approximately $508,000.
A number of other hedge funds also recently bought and sold shares of EXEL. Norges Bank purchased a new stake in Exelixis in the 4th quarter valued at approximately $54,640,000. Oregon Public Employees Retirement Fund lifted its stake in Exelixis by 1,978.9% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,319,939 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 2,208,347 shares in the last quarter. Fiera Capital Corp purchased a new stake in Exelixis in the 4th quarter valued at approximately $39,370,000. Prudential Financial Inc. lifted its stake in Exelixis by 451.9% in the 4th quarter. Prudential Financial Inc. now owns 1,598,167 shares of the biotechnology company’s stock valued at $31,435,000 after buying an additional 1,308,617 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in Exelixis by 19.5% in the 4th quarter. First Trust Advisors LP now owns 5,551,138 shares of the biotechnology company’s stock valued at $109,191,000 after buying an additional 907,412 shares in the last quarter. 75.95% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on EXEL. BidaskClub lowered Exelixis from a “buy” rating to a “hold” rating in a research note on Tuesday. Oppenheimer reaffirmed a “buy” rating on shares of Exelixis in a research note on Tuesday, March 19th. Morgan Stanley raised Exelixis from an “underweight” rating to an “equal weight” rating and set a $24.80 target price on the stock in a research note on Monday, March 18th. ValuEngine raised Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Finally, Zacks Investment Research raised Exelixis from a “strong sell” rating to a “hold” rating in a research note on Monday, March 4th. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $29.78.
Shares of Exelixis stock opened at $23.01 on Tuesday. Exelixis, Inc. has a fifty-two week low of $13.42 and a fifty-two week high of $25.31. The firm has a market cap of $6.93 billion, a price-to-earnings ratio of 16.09, a price-to-earnings-growth ratio of 0.47 and a beta of 2.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.41 and a current ratio of 8.50.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The company had revenue of $228.60 million for the quarter, compared to analyst estimates of $188.44 million. During the same quarter in the prior year, the company posted $0.12 EPS. The business’s revenue for the quarter was up 90.4% compared to the same quarter last year. Analysts expect that Exelixis, Inc. will post 1.08 earnings per share for the current fiscal year.
In other news, Director Charles Cohen sold 248,180 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $22.14, for a total transaction of $5,494,705.20. Following the completion of the sale, the director now directly owns 148,180 shares in the company, valued at approximately $3,280,705.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Michael Morrissey sold 40,000 shares of the company’s stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $23.29, for a total value of $931,600.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,044,101 shares of company stock worth $23,878,224. Corporate insiders own 4.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Toth Financial Advisory Corp Invests $508,000 in Exelixis, Inc. (EXEL) Stock” was originally posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://macondaily.com/2019/04/16/toth-financial-advisory-corp-invests-508000-in-exelixis-inc-exel-stock.html.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: What is intrinsic value?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.